Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 5NIH 4OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 3

Interventions

Magnetic Resonance Spectroscopy 81Specimen Handling 80Cyclophosphamide 72pembrolizumab 61Nivolumab 53Radiotherapy 52fludarabine 43Cisplatin 42Biopsy 40Carboplatin 38Standard of Care 35Dexamethasone 31Radiation 30Bevacizumab 30Rituximab 29Surveys and Questionnaires 27Radiosurgery 26Doxorubicin 26Temozolomide 25Gemcitabine 25Cytarabine 25Blood Specimen Collection 25venetoclax 24Practice Guidelines as Topic 24Paclitaxel 24fludarabine phosphate 23Ipilimumab 21atezolizumab 20Vincristine 20Interviews as Topic 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × relatlimab × 30 days × Clear all
NCT07281924 2026-05-29

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

University of Wisconsin, Madison

Phase 1/2 Recruiting
15 enrolled
Dermatologic

Melanoma

NCT05034536 2026-05-18

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

Massachusetts General Hospital

Phase 2 Active not recruiting
36 enrolled
Dermatologic

Melanoma

NCT05704647 2026-05-15

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡